Supernus Pharmaceuticals Inc (SUPN) 8.80 $SUPN
Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 3:00PM CST
Supernus Pharmaceuticals, Inc. (SUPN) filed a patent infringement lawsuit against TWi accusing the latter of infringement of four patents covering Oxtellar XR.
IPXL: 39.51 (+0.69), ACT: 285.37 (+3.71), SUPN: 8.80 (+0.22), TEVA: 56.77 (-0.58)
Supernus Sues TWi for Infringement of Oxtellar XR(R) Patents
GlobeNewswire - Wed Jan 21, 3:30PM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers TWi Pharmaceuticals, Inc. and TWi International LLC (d/b/a TWi Pharmaceuticals USA) (collectively "TWi"
for infringement of four patents covering its antiepileptic drug Oxtellar XR(R). Supernus' United States Patents Nos. 7,722,898, 7,910,131, 8,617,600 and 8,821,930 cover once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. Patent protection for Oxtellar XR expires in 2027.
SUPN: 8.80 (+0.22)
Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 4:00PM CST
Zacks Investment Research downgraded Supernus Pharmaceuticals (SUPN) to a Zacks Rank #4 (Sell) on Jan 20.
SUPN: 8.80 (+0.22), ALXN: 182.29 (+6.02), AMGN: 153.48 (+0.30), CELG: 115.88 (+0.16)
Supernus Sues Par for Infringement of Trokendi XR(R) Patents
GlobeNewswire - Fri Jan 16, 4:00PM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. (collectively "Par" for infringement of four patents covering its antiepileptic drug Trokendi XR(R). Supernus' United States Patents Nos. 8,298,576, 8,298,580, 8,663,683 and 8,877,248 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR expires no earlier than 2027.
SUPN: 8.80 (+0.22)
Supernus Pharmaceuticals (SUPN) Is Strong On High Volume Today
at The Street - Wed Jan 14, 9:17AM CST
Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a strong on high relative volume candidate
SUPN: 8.80 (+0.22)
Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 3:35PM CST
Actavis plc (ACT) confirmed that the U.S. Court of Appeals for the Second Circuit has granted the company's motion to expedite its appeal of a lower court ruling in Dec 2014, whereby Actavis was required to continue distribution of Namenda immediate-release (IR) tablets.
PGNX: 5.66 (+0.06), ACT: 285.37 (+3.71), SUPN: 8.80 (+0.22), MYL: 55.85 (+1.34)
KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 1:28PM CST
KaloBios Pharmaceuticals, Inc. (KBIO) announced that one of its principal candidates, KB001-A, has failed to meet the primary endpoint in a phase II study.
PGNX: 5.66 (+0.06), ACT: 285.37 (+3.71), KBIO: 0.45 (+0.06), SUPN: 8.80 (+0.22)
Commit To Purchase Supernus Pharmaceuticals At $5, Earn 7% Using Options
StockOptionsChannel.com - Mon Dec 29, 10:41AM CST
Investors eyeing a purchase of Supernus Pharmaceuticals Inc shares, but tentative about paying the going market price of $8.40/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
SUPN: 8.80 (+0.22)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 39.51 (+0.69), CHTP: 6.52 (-0.03), SUPN: 8.80 (+0.22), ITCI: 24.53 (+2.45), LLY: 70.56 (+0.03), DRRX: 1.00 (+0.03)
Why Supernus Pharmaceuticals (SUPN) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 7:54AM CST
Supernus Pharmaceuticals has been overlooked by investors but it has actually seen estimates rise over the past month.
SUPN: 8.80 (+0.22)
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:20PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Para IV notice from TWi Pharma, seeking approval for its generic version of Supernus' Oxtellar XR in the U.S.
ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), SUPN: 8.80 (+0.22), MYL: 55.85 (+1.34)
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:50PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Par, which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), SUPN: 8.80 (+0.22), MYL: 55.85 (+1.34)
Supernus receives Paragraph IV ANDA filing for Trokendi XR from Par Pharmaceutical
M2 - Wed Dec 10, 6:32AM CST
Specialist pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) reported on Tuesday that it has received a Paragraph IV Notice Letter from Par Pharmaceutical for the filing of an Abbreviated New Drug Application for topiramate extended-release capsules.
SUPN: 8.80 (+0.22)
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R)
GlobeNewswire - Wed Dec 10, 6:30AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on December 9, 2014 the Company received a Paragraph IV Notice Letter from TWi Pharmaceuticals, Inc. ("TWi" advising Supernus of the filing by TWi of an Abbreviated New Drug Application seeking approval for oxcarbazepine extended-release tablets. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Oxtellar XR. The product is currently protected by four issued patents that expire no earlier than 2027.
SUPN: 8.80 (+0.22)
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R)
GlobeNewswire - Tue Dec 09, 8:12AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on December 8, 2014 the Company received a Paragraph IV Notice Letter from Par Pharmaceutical, Inc. ("Par" advising Supernus of the filing by Par of an Abbreviated New Drug Application seeking approval for topiramate extended-release capsules. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Trokendi XR. The product is currently protected by five issued patents that expire no earlier than 2027.
SUPN: 8.80 (+0.22)
Why Supernus Pharmaceuticals (SUPN) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 7:30AM CST
Supernus Pharmaceuticals (SUPN) has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on SUPN’s earnings for the coming quarter and year.
SUPN: 8.80 (+0.22)
How Supernus Pharmaceuticals (SUPN) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 8:01AM CST
Supernus Pharmaceuticals is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 27
SUPN: 8.80 (+0.22)
Supernus receives fifth US patent for the antiepileptic drug Trokendi XR
M2 - Tue Nov 25, 8:15AM CST
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) revealed on Monday the receipt of the fifth patent from the US Patent and Trademark Office (USPTO) covering its novel once-daily extended-release topiramate product, Trokendi XR.
SUPN: 8.80 (+0.22)
Supernus Files Trokendi XR Patent Infringement Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 5:00PM CST
Supernus Pharmaceuticals, Inc. (SUPN) filed a patent infringement lawsuit against Zydus accusing the latter of infringement of three patents covering Trokendi XR.
IPXL: 39.51 (+0.69), ACT: 285.37 (+3.71), SUPN: 8.80 (+0.22), MYL: 55.85 (+1.34)
Supernus Announces Issuance of Fifth U.S. Patent Protecting Trokendi XR(R)
GlobeNewswire - Mon Nov 24, 6:30AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a fifth patent (number 8,889,191) by the United States Patent and Trademark Office (USPTO) covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.
SUPN: 8.80 (+0.22)
Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 3:00PM CST
Supernus Pharmaceuticals, Inc. (SUPN) filed a patent infringement lawsuit against TWi accusing the latter of infringement of four patents covering Oxtellar XR.
IPXL: 39.51 (+0.69), ACT: 285.37 (+3.71), SUPN: 8.80 (+0.22), TEVA: 56.77 (-0.58)
Supernus Sues TWi for Infringement of Oxtellar XR(R) Patents
GlobeNewswire - Wed Jan 21, 3:30PM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers TWi Pharmaceuticals, Inc. and TWi International LLC (d/b/a TWi Pharmaceuticals USA) (collectively "TWi"
for infringement of four patents covering its antiepileptic drug Oxtellar XR(R). Supernus' United States Patents Nos. 7,722,898, 7,910,131, 8,617,600 and 8,821,930 cover once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. Patent protection for Oxtellar XR expires in 2027. SUPN: 8.80 (+0.22)
Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 4:00PM CST
Zacks Investment Research downgraded Supernus Pharmaceuticals (SUPN) to a Zacks Rank #4 (Sell) on Jan 20.
SUPN: 8.80 (+0.22), ALXN: 182.29 (+6.02), AMGN: 153.48 (+0.30), CELG: 115.88 (+0.16)
Supernus Sues Par for Infringement of Trokendi XR(R) Patents
GlobeNewswire - Fri Jan 16, 4:00PM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. (collectively "Par"
for infringement of four patents covering its antiepileptic drug Trokendi XR(R). Supernus' United States Patents Nos. 8,298,576, 8,298,580, 8,663,683 and 8,877,248 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR expires no earlier than 2027. SUPN: 8.80 (+0.22)
Supernus Pharmaceuticals (SUPN) Is Strong On High Volume Today
at The Street - Wed Jan 14, 9:17AM CST
Trade-Ideas LLC identified Supernus Pharmaceuticals (SUPN) as a strong on high relative volume candidate
SUPN: 8.80 (+0.22)
Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 3:35PM CST
Actavis plc (ACT) confirmed that the U.S. Court of Appeals for the Second Circuit has granted the company's motion to expedite its appeal of a lower court ruling in Dec 2014, whereby Actavis was required to continue distribution of Namenda immediate-release (IR) tablets.
PGNX: 5.66 (+0.06), ACT: 285.37 (+3.71), SUPN: 8.80 (+0.22), MYL: 55.85 (+1.34)
KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 1:28PM CST
KaloBios Pharmaceuticals, Inc. (KBIO) announced that one of its principal candidates, KB001-A, has failed to meet the primary endpoint in a phase II study.
PGNX: 5.66 (+0.06), ACT: 285.37 (+3.71), KBIO: 0.45 (+0.06), SUPN: 8.80 (+0.22)
Commit To Purchase Supernus Pharmaceuticals At $5, Earn 7% Using Options
StockOptionsChannel.com - Mon Dec 29, 10:41AM CST
Investors eyeing a purchase of Supernus Pharmaceuticals Inc shares, but tentative about paying the going market price of $8.40/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
SUPN: 8.80 (+0.22)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 39.51 (+0.69), CHTP: 6.52 (-0.03), SUPN: 8.80 (+0.22), ITCI: 24.53 (+2.45), LLY: 70.56 (+0.03), DRRX: 1.00 (+0.03)
Why Supernus Pharmaceuticals (SUPN) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 7:54AM CST
Supernus Pharmaceuticals has been overlooked by investors but it has actually seen estimates rise over the past month.
SUPN: 8.80 (+0.22)
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:20PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Para IV notice from TWi Pharma, seeking approval for its generic version of Supernus' Oxtellar XR in the U.S.
ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), SUPN: 8.80 (+0.22), MYL: 55.85 (+1.34)
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:50PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Par, which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), SUPN: 8.80 (+0.22), MYL: 55.85 (+1.34)
Supernus receives Paragraph IV ANDA filing for Trokendi XR from Par Pharmaceutical
M2 - Wed Dec 10, 6:32AM CST
Specialist pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) reported on Tuesday that it has received a Paragraph IV Notice Letter from Par Pharmaceutical for the filing of an Abbreviated New Drug Application for topiramate extended-release capsules.
SUPN: 8.80 (+0.22)
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R)
GlobeNewswire - Wed Dec 10, 6:30AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on December 9, 2014 the Company received a Paragraph IV Notice Letter from TWi Pharmaceuticals, Inc. ("TWi"
advising Supernus of the filing by TWi of an Abbreviated New Drug Application seeking approval for oxcarbazepine extended-release tablets. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Oxtellar XR. The product is currently protected by four issued patents that expire no earlier than 2027. SUPN: 8.80 (+0.22)
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R)
GlobeNewswire - Tue Dec 09, 8:12AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on December 8, 2014 the Company received a Paragraph IV Notice Letter from Par Pharmaceutical, Inc. ("Par"
advising Supernus of the filing by Par of an Abbreviated New Drug Application seeking approval for topiramate extended-release capsules. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Trokendi XR. The product is currently protected by five issued patents that expire no earlier than 2027. SUPN: 8.80 (+0.22)
Why Supernus Pharmaceuticals (SUPN) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 7:30AM CST
Supernus Pharmaceuticals (SUPN) has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on SUPN’s earnings for the coming quarter and year.
SUPN: 8.80 (+0.22)
How Supernus Pharmaceuticals (SUPN) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 8:01AM CST
Supernus Pharmaceuticals is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 27
SUPN: 8.80 (+0.22)
Supernus receives fifth US patent for the antiepileptic drug Trokendi XR
M2 - Tue Nov 25, 8:15AM CST
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) revealed on Monday the receipt of the fifth patent from the US Patent and Trademark Office (USPTO) covering its novel once-daily extended-release topiramate product, Trokendi XR.
SUPN: 8.80 (+0.22)
Supernus Files Trokendi XR Patent Infringement Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 5:00PM CST
Supernus Pharmaceuticals, Inc. (SUPN) filed a patent infringement lawsuit against Zydus accusing the latter of infringement of three patents covering Trokendi XR.
IPXL: 39.51 (+0.69), ACT: 285.37 (+3.71), SUPN: 8.80 (+0.22), MYL: 55.85 (+1.34)
Supernus Announces Issuance of Fifth U.S. Patent Protecting Trokendi XR(R)
GlobeNewswire - Mon Nov 24, 6:30AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a fifth patent (number 8,889,191) by the United States Patent and Trademark Office (USPTO) covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.
SUPN: 8.80 (+0.22)
